Logo

Sanofi Divulges its Strategic Framework to Drive Innovation and Growth

Share this

Sanofi Divulges its Strategic Framework to Drive Innovation and Growth

Shots:

  • Sanofi reveals its focus on its key growth drivers including Dupixent (dupilumab)- vaccines and its pipeline consisting of six potentially transformative therapies. The company is expecting Dupixent to generate ~$11B in its annual sales
  • Sanofi also reveals its six investigational therapies which include Fitusiran- BIVV001- Venglustat- SERD (‘859)- Nirsevimab- BTKi (‘168) and plan its R&D day in 2020 to provide a detailed review of its R&D portfolio. Sanofi has decided to terminate further research in diabetes & will not pursue plans to launch efpeglenatide
  • Sanofi expects to expand its BOI margin to 30% by 2022 with an aim to exceed it to 32% by 2025. It also plans to separate its OTC business and cut $2.21B in operating costs by 2022. Sanofi will shift its focus to specialty care (immunology- rare diseases- rare blood disorders- neurology and oncology)- vaccines and general medicines

Click here to­ read full press release/ article | Ref: GlobeNewswire | Image: Behance


Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions